Moberg Pharma AB (FRA:MB8) ROCE %: -0.72% (As of Mar. 2026)


FRA:MB8 Moberg Pharma AB FRA:MB8
59 GF Score
Price €0.79
GF Value €1.09
! 1 Warning Sign
View Full Analysis

What is Moberg Pharma AB ROCE %?

Moberg Pharma AB FRA:MB8 -2.95% 59 ROCE % is -0.72% as of Mar. 2026. GuruFocus rates FRA:MB8 with a GF Score™ of 59/100 and a GF Value™ of €1.09. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Moberg Pharma AB's annualized ROCE % for the quarter that ended in Mar. 2026 was -0.72%.

Moberg Pharma AB  (FRA:MB8) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Moberg Pharma AB ROCE % Related Terms

Moberg Pharma AB ROCE % Historical Data

* Premium members only.

The historical data trend for Moberg Pharma AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moberg Pharma AB ROCE % Chart

Moberg Pharma AB Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec21 Dec22 Dec23 Dec24
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.93 -2.43 -3.87 -4.33 -48.49

Moberg Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.86 -5.04 -3.02 -4.14 -0.72
FRA:MB8
59GF Score
Moberg Pharma AB FRA:MB8
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Moberg Pharma AB ROCE % Calculation

Moberg Pharma AB's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-27.841/( ( (56.743 - 1.836) + (61.385 - 1.454) )/ 2 )
=-27.841/( (54.907+59.931)/ 2 )
=-27.841/57.419
=-48.49 %

Moberg Pharma AB's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-0.444/( ( (62.695 - 1.486) + (63.454 - 1.662) )/ 2 )
=-0.444/( ( 61.209 + 61.792 )/ 2 )
=-0.444/61.5005
=-0.72 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -0.72% mean?
Moberg Pharma AB (FRA:MB8) has a ROCE % of -0.72% as of Mar. 2026.
Is Moberg Pharma AB's ROCE % too high?
Moberg Pharma AB's current ROCE % is -0.72%. Overall, Moberg Pharma AB has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Moberg Pharma AB's ROCE % compare to ZTS?
Moberg Pharma AB's ROCE % of -0.72% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moberg Pharma AB's current ROCE % is -0.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moberg Pharma AB stock overvalued right now?
Moberg Pharma AB (FRA:MB8) has a current ROCE % of -0.72%. The stock's GF Value™ is €1.09, compared to a current price of €0.79 — trading 27.6% below its estimated fair value. The current ROCE % is -0.72%. Moberg Pharma AB's overall GF Score™ is 59/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Moberg Pharma AB (FRA:MB8), the current ROCE % is -0.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Moberg Pharma AB (FRA:MB8) Overvalued in 2026?

Based on GuruFocus' analysis, Moberg Pharma AB stock appears to be undervalued. The current stock price of €0.79 is trading 27.6% below its estimated GF Value™ of €1.09.

Key valuation signals for FRA:MB8:

  • ROCE %: -0.72%
  • GF Value™: €1.09 vs. price of €0.79 (27.6% below fair value)
  • GF Score™: 59/100 with 1 warning sign

No single metric tells the full story. See the FRA:MB8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Moberg Pharma AB Business Description

Other Exchanges MBGPF:USAMOB:Sweden
Address Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
59GF Score

Get the complete analysis for FRA:MB8

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.79
Price
€1.09
GF Value